GW-501516 (Cardarine) – PPARδ Receptor Agonist

Enhance Endurance, Support Fat Loss, and Optimize Metabolic Health

Cardarine (GW-501516) is a potent PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist, originally developed by Ligand Pharmaceuticals and GlaxoSmithKline to treat metabolic syndrome, obesity, and cardiovascular disease. Although its development was discontinued after long-term animal studies, Cardarine continues to be studied in research settings due to its unique ability to promote fat metabolism, enhance endurance, and support cardiovascular health.

GW-501516 is not a SARM, but is often stacked with SARMs due to its non-hormonal nature and performance-enhancing benefits. It has been widely researched for its ability to increase mitochondrial activity, boost fatty acid oxidation, and improve VO2 max, making it popular in sports and endurance-based applications.

💊 Key Details:

• Compound: GW-501516 (Cardarine / Endurobol)

• Category: PPARδ Agonist (not a SARM)

• Originally developed for: Metabolic and cardiovascular health

• Form: Oral – high bioavailability

✅ Why Researchers Use GW-501516:

• Supports fat burning and metabolic efficiency

• Enhances aerobic capacity and endurance performance

• Aids in preserving lean muscle during caloric deficits

• Non-hormonal: No testosterone suppression

• May support cardiovascular and lipid health

Cardarine is often used in research focused on cutting cycles, body recomposition, or endurance performance. Its ability to shift the body’s energy source from glucose to fat is a primary reason why it has attracted significant interest in the performance science field.

📦 Common Use Cases (Research Purposes Only):

• Endurance and stamina enhancement

• Fat oxidation and weight management studies

• Non-hormonal performance supplementation

• Athletic and cardiovascular conditioning support